Varset-for-a Masked Approach (3/1/26-3/22/26)

If you have any questions, please reach out at [email protected] or on Twitter/X @tdonatellov. Thank you for listening!Topics:CytomX’s Varsetatug Masetecan (EpCAM PROBODY® ADC) Continues to Demonstrate Positive Data Supporting Potential as a New Treatment Option in Late-Line Colorectal CancerBristol Myers Squibb Announces Positive Phase 3 Results from the SUCCESSOR-2 Study of Oral Mezigdomide in Relapsed or Refractory Multiple MyelomaRelmada Therapeutics Reports 12-Month Phase 2 Interim Data for NDV-01 in Non-Muscle Invasive Bladder CancerGenentech Provides Update on Phase III persevErA Study in ER-Positive Advanced Breast CancerPfizer Announces Positive Topline Phase 2 Results for Next-Generation CDK4 Inhibitor, Atirmociclib, in Second-Line Metastatic Breast Cancer